PharmAla Announces Changes to Board of Directors
MWN-AI** Summary
PharmAla Biotech Holdings Inc., a Toronto-based biotechnology company focused on the research, development, and manufacturing of LaNeo™ MDMA and its derivatives, has announced notable changes to its Board of Directors as of February 9, 2026. The company has accepted the resignation of Dr. Malik Slassi, a founding member who played a pivotal role during PharmAla's early stages. CEO Nicholas Kadysh expressed gratitude for Dr. Slassi’s contributions over the past four years and emphasized the importance of his guidance during the company’s formative period.
In a positive transition, Mr. Lennie Ryer, CPA, CA, has been appointed to the board. Ryer brings a wealth of experience in corporate finance and governance from his extensive background in the pharmaceutical and biotechnology sectors. His career includes senior roles such as Chief Financial Officer and Vice President of Finance, along with experience as Managing Partner at a prominent public accounting firm where he specialized in mergers, acquisitions, and capital markets. Ryer is expected to provide critical financial expertise as PharmAla progresses into its next developmental phase.
PharmAla continues to position itself as a leader in the psychedelics industry by addressing the supply of clinical-grade MDMA and developing novel MDXX class molecules. The company is noted for its dedication to regulating practices within the psychedelic field while fostering relationships with regulatory bodies. With Ryer's appointment and the resignation of Slassi, PharmAla aims to strengthen its executive governance as it navigates the evolving landscape of biotechnology and psychedelics. For further inquiries, stakeholders may reach out to CEO Nicholas Kadysh via email or phone as listed.
MWN-AI** Analysis
PharmAla Biotech Holdings Inc. has made a strategic move by reshaping its Board of Directors, which reflects its evolving ambitions in the rapidly growing psychedelics market. The resignation of Dr. Malik Slassi, a founding member, marks the end of an era and emphasizes the company's transition towards a more finance-oriented strategic leadership with the addition of Mr. Lennie Ryer. His extensive experience in corporate finance, governance, and capital market transitions could bring valuable insight as PharmAla prepares to enhance its operational frameworks and potentially navigate public markets more effectively.
Investors should closely monitor this change as it might signal a shift in strategy that focuses on scaling operations and leveraging financial markets for growth. Ryer's proven expertise in mergers and acquisitions and familiarity with the pharmaceutical and biotech industries aligns well with PharmAla's ongoing development of MDXX class molecules, particularly its lead candidate ALA-002. This focus on innovation coupled with strategic finance management could bolster investor confidence and result in a positive long-term outlook for PharmAla.
As PharmAla aims to be at the forefront of supplying clinical-grade MDMA for therapeutic uses, ongoing partnerships and regulatory relationships will be critical. Investors should remain aware of how the company navigates the potentially volatile landscape of psychedelics regulation, as this could significantly impact market positioning and share valuation.
For those looking to invest, the current reconfiguration may present a buying opportunity, particularly if the stock reacts positively to Ryer's appointment. However, prospective buyers should exercise caution, keeping the inherent uncertainties within the biotech sector and the regulatory landscape in mind. Monitoring PharmAla's subsequent announcements and financial reports will be essential for making informed investment decisions.
**MWN-AI Summary and Analysis is based on asking OpenAI to summarize and analyze this news release.
TORONTO, Feb. 10, 2026 (GLOBE NEWSWIRE) -- PharmAla Biotech Holdings Inc. (“PharmAla” or the “Company”) (CSE: MDMA) (OTCQB:MDXXF), a biotechnology company focused on the research, development, and manufacturing of LaNeo™ MDMA and novel derivatives of MDMA (MDXX class molecules), is pleased to announce changes to the makeup of its Board of Directors.
Effective Monday, February 9, 2026, PharmAla regretfully accepts the resignation of Dr. Malik Slassi. Also effective February 9, 2026, PharmAla has appointed Mr. Lennie Ryer, CPA, CA, of Montreal to its board of directors.
“Dr. Slassi was one of the first people I approached when PharmAla was just an idea, not yet a company. We are immeasurably grateful for his support and insight over the past 4 years,” said Nicholas Kadysh, CEO, PharmAla Biotech. “However, we are excited to welcome Mr. Lennie Ryer to the board; Having been working with Mr. Ryer for over a month already, I believe he will bring much-needed experience and expertise to the PharmAla board as we enter the next phase of our development.”
Lennie Ryer, CPA, CA is a seasoned financial executive and board director with extensive experience in corporate finance, governance, and strategic leadership. Throughout his career, Mr. Ryer has held numerous senior roles including Chief Financial Officer and Vice President of Finance for companies in the pharmaceutical, biotechnology, and technology sectors. He has also served as Managing Partner of a major public accounting firm, where he specialized in mergers and acquisitions, taxation, and capital markets. Lennie’s background includes guiding companies through transitions to public markets and leading significant equity and debt financings. He holds a Bachelor of Commerce in Finance and a Public Accountancy degree from McGill University and is a Chartered Professional Accountant (CPA, CA).
About PharmAla
PharmAla Biotech Holdings Inc. (CSE: MDMA)(OTCQB: MDXXF) is a biotechnology company focused on the research, development, and manufacturing of MDXX class molecules, including MDMA. PharmAla was founded with a dual focus: alleviating the global backlog of generic, clinical-grade MDMA to enable clinical trials as well as commercial sales in selected jurisdictions, and to develop novel drugs in the same class. PharmAla is the only company currently provisioning clinical-grade MDMA for patient treatments outside of clinical trials. PharmAla’s research and development unit has completed proof-of-concept research into several IP families, including ALA-002, its lead drug candidate. PharmAla is a “regulatory first” organization, formed under the principle that true success in the psychedelics industry will only be achieved through excellent relationships with regulators.
For more information, please contact:
Nicholas Kadysh
Chief Executive Officer
PharmAla Biotech Holdings Inc.
Email: press@PharmAla.ca
Phone: 1-855-444-6362
Website: www.PharmAla.ca
Neither the Canadian Securities Exchange nor its Regulation Services Provider have reviewed or accept responsibility for the adequacy or accuracy of this release.
Cautionary Statement
This press release contains ‘forward-looking information’ within the meaning of applicable Canadian securities legislation. These statements relate to future events or future performance. The use of any of the words “could”, “intend”, “expect”, “believe”, “will”, “projected”, “estimated” and similar expressions and statements relating to matters that are not historical facts are intended to identify forward-looking information and are based on PharmAla’s current belief or assumptions as to the outcome and timing of such future events. Forward-looking information is based on reasonable assumptions that have been made by PharmAla at the date of the information and is subject to known and unknown risks, uncertainties, and other factors that may cause actual results or events to differ materially from those anticipated in the forward-looking information. The forward-looking information contained in this press release is made as of the date hereof, and PharmAla is not obligated to update or revise any forward-looking information, whether as a result of new information, future events or otherwise, except as required by applicable securities laws. Factors that could cause actual results to differ materially from those anticipated in these forward-looking statements are described under the caption “Risk Factors” in PharmAla’s management’s discussion and analysis which is available on PharmAla’s profile at www.sedar.com.
This news release does not constitute an offer to sell or the solicitation of an offer to buy, and shall not constitute an offer, solicitation or sale in any state, province, territory or jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state, province, territory or jurisdiction.
FAQ**
How might the recent changes to the Board of Directors, particularly the appointment of Mr. Lennie Ryer, impact PharmAla's (CSE: MDMA) strategy and growth trajectory in the MDXXF market?
With Mr. Ryer's expertise in corporate finance and transitions to public markets, what specific initiatives does PharmAla plan to pursue to enhance its MDXXF positioning?
As PharmAla seeks to alleviate the backlog of clinical-grade MDMA, what challenges do you foresee in the regulatory landscape, and how might this affect the MDXXF segment?
Can you elaborate on the proof-of-concept research results from PharmAla’s R&D unit, particularly how these developments may influence the market perception of MDXXF products?
**MWN-AI FAQ is based on asking OpenAI questions about Pharmala Biotech Holdings Inc. (CNQC: MDMA:CC).
NASDAQ: MDMA:CC
MDMA:CC Trading
0.0% G/L:
$0.03 Last:
163,753 Volume:
$0.03 Open:
